CARP-1 functional mimetics are a novel class of small molecule inhibitors of malignant pleural mesothelioma cells

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Jamal, Shazia ^a,b,g   Cheriyan, Vino T ^a,b   Muthu, Magesh ^a,b   Munie, Sara ^a,b   Levi, Edi ^a,b   Ashour, Abdelkader E ^c   Pass, Harvey I ^d   Wali, Anil ^a,f   Singh, Mandip ^e   Rishi, Arun K ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d NEW YORK UNIVERSITY   (United States)

^e FLORIDA A AND M UNIVERSITY   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g B S ABDUR RAHMAN CRESCENT INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; DEATH RECEPTOR 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PODOPLANIN; SERINE; STRESS ACTIVATED PROTEIN KINASE; VIMENTIN; 1-(2-CHLOROBENZYL)-5'-PHENYL-3'H-SPIRO(INDOLINE-3,2'-(1,3,4)THIADIAZOL)-2-ONE; ANTINEOPLASTIC AGENT; CISPLATIN; MATRIX METALLOPROTEINASE; MEMBRANE PROTEIN; PDPN PROTEIN, HUMAN; SPIRO COMPOUND; THIADIAZOLE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CLINICAL EFFECTIVENESS; CLONOGENIC ASSAY; HUMAN; IMMUNOPRECIPITATION; IN VITRO STUDY; METASTASIS; MOLECULAR MECHANICS; ONCOGENE C MYC; PLEURA MESOTHELIOMA; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; AMINO ACID SEQUENCE; CELL MOTION; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; EPITHELIAL MESENCHYMAL TRANSITION; LUNG TUMOR; MESOTHELIOMA; METABOLISM; MOLECULAR MIMICRY; PHOSPHORYLATION; PLEURA TUMOR; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASES; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MOLECULAR MIMICRY; NEOPLASM INVASIVENESS; NF-KAPPA B; PHOSPHORYLATION; PLEURAL NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; SPIRO COMPOUNDS; THIADIAZOLES;

EID: 84897143170     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089146     Document Type: Article

References (57)

1. Kamp DW (2009) Asbestos-induced lung diseases: an update. Transl Res 153(4): 143-52.
2. Su S (2009) Mesothelioma: path to multimodality treatment. Semin Thorac Cardiovasc Surg 21(2): 125-31.
3. Tsao AS, Wistuba I, Roth JA, Kindler HL (2009) Malignant pleural mesothelioma. J Clin Oncol 27(12): 2081-90.
4. Peto J, Decarli A, La Vecchia C, Levi F, Negri E (1999) The European mesothelioma epidemic. Br J Cancer 79(3-4): 666-72. (Pubitemid 29046253)
5. Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, Meerbeeck JV (2008) Advances in systemic therapy of malignant pleural mesothelioma. Nature Clinical Practice Oncology 5: 136-147.
6. Rishi AK, Zhang L, Boyanapalli M, Wali A, Mohammad RM, et al. (2003) Identification and characterization of a Cell-Cycle and Apoptosis Regulatory Protein (CARP)-1 as a novel mediator of apoptosis signaling by Retinoid CD437. J Biol Chem 278: 33422-33435. (Pubitemid 37055796)
7. Kim JH, Yang CK, Heo K, Roeder RG, An W, et al. (2008) CCAR1, a key regulator of mediator complex recruitment to nuclear receptor transcription complexes. Mol Cell 31: 510-519.
8. Rishi AK, Zhang L, Yu Y, Jiang Y, Nautiyal J, et al. (2006) Cell cycle and apoptosis regulatory protein (CARP)-1 is involved in apoptosis signaling by epidermal growth factor receptor. J Biol Chem 281(19): 13188-98. (Pubitemid 43855230)
9. Jiang Y, Puliyappadamba VT, Zhang L, Wu W, Wali A, et al. (2010) A novel mechanism of cell growth regulation by cell cycle and apoptosis regulatory protein (CARP)-1. J Mol Signaling 5: 7.
10. Beausoleil SA, Jedrychowski M, Schwartz D, Elias JE, Villen J, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci USA 101: 12130-12135. (Pubitemid 39145408)
11. Blagoev B, Kratchmarova I, Ong SE, Nielsen M, Foster LJ, et al. (2003) A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling. Nat Biotechnol 21: 315-318. (Pubitemid 36314817)
12. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316: 1160-1166. (Pubitemid 46877472)
13. Zachariae W, Nasmyth K (1999) Whose end is destruction: cell division and the anaphase-promoting complex. Genes Dev 13: 2039-2058. (Pubitemid 29407346)
14. Lehman NL, Tibshirani R, Hsu JY, Natkunam Y, Harris BT, et al. (2007) Oncogenic Regulators and Substrates of the Anaphase Promoting Complex/Cyclosome Are Frequently Overexpressed in Malignant Tumors. Am J Pathol 170(5): 1793-1805. (Pubitemid 47339321)
15. Puliyappadamba VT, Wu W, Bevis D, Zhang L, Polin L, et al. (2011) Antagonists of anaphase promoting complex (APC)-2-cell cycle and apoptosis regulatory protein (CARP)-1 interaction are novel regulators of cell growth and apoptosis. J Biol Chem 286 (44): 38000-38017.
16. Pass HI, Stevens EJ, Oie H, Tsokos MG, Abati AD, et al. (1995) Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg 59: 835-44.
17. Okada M, Sterman D, Wiewrodt R, Zhang Y, Kiefer M, et al. (2001) Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-b gene therapy due to induction of systemic immunity. Cancer Res 61: 6201-6212. (Pubitemid 32762558)
18. Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2(2): 329-33. (Pubitemid 47040047)
19. Zhang L, Levi E, Majumder P, Yu Y, Aboukameel A, et al. (2007) Transactivator of transcription tagged cell cycle and apoptosis regulatory protein-1 peptides suppress growth of human breast cancer cells in vitro and in vivo. Mol Cancer Ther 6(5): 1661-1672. (Pubitemid 46954033)
20. Ashour AE, Jamal S, Cheryan VT, Muthu M, Zoheir KMA, et al. (2013) CARP-1 functional mimetics: A novel class of small molecule inhibitors of medulloblastoma cell growth. PLoS One 8(6); e66733.
21. Schwenger P, Alpert D, Skolnik EY, Vilcek J (1998) Activation of p38 mitogenactivated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IκBα phosphorylation and degradation. Mol Cell Biol 18: 78-84. (Pubitemid 28021019)
22. Tan J, Kuang W, Jin Z, Jin F, Xu L, et al. (2009) Inhibition of NFkappaB by activated c-Jun NH2 terminal kinase 1 acts as a switch for C2C12 cell death under excessive stretch. Apoptosis 14: 764-770.
23. Karl S, Pritschow Y, Volcic M, Hacker S, Baumann B, et al. (2009) Identification of a novel pro-apoptotic function of NF-κB in the DNA damage response. J Cell Mol Med 13: 4239-4256.
24. Liu J, Yang D, Minemoto Y, Leitges M, Rosner MR, et al. (2006) NF-κB Is Required for UV-Induced JNK Activation via Induction of PKCδ. Mol Cell 21: 467-480. (Pubitemid 43228003)
25. Berger R, Jennewein C, Marscall V, Karl S, Cristofanson S, et al. (2011) NF-κB Is Required for Smac Mimetic-Mediated Sensitization of Glioblastoma Cells for γ-Irradiation-Induced Apoptosis. Mol Cancer Ther 10: 1867-75.
26. Perkins ND (2007) Integrating cell-signalling pathways with NF-κB and IKK function. Nature Rev Mol Cell Biol 8: 49-62.
27. Verstrepen L, Carpentier I, Verhelst K, Beyaert R (2009) ABINs: A20 binding inhibitors of NF-κB and apoptosis signaling. Biochem Pharmacol 28: 105-114.
28. Liu W-K, Yen P-F, Chien C-Y, Fann M-J, Su J-Y, et al. (2004) The inhibitor ABIN-2 disrupts the interaction of receptor-interacting protein with the kinase subunit IKKγ to block activation of the transcription factor NF-κB and potentiate apoptosis. Biochem J 378: 867-876. (Pubitemid 38406864)
29. Ashkenazi A (2002) Targeting death and decoy receptors of the tumournecrosis factor superfamily. Nat Rev 2: 420-30.
30. Degli-Esposti MA, Smolak PJ, Walczak H, et al. (1997) Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 186: 1165-70. (Pubitemid 27441160)
31. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, et al. (1997) The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity7: 813-20. (Pubitemid 28064894)
32. Marsters SA, Sheridan JP, Pitti RM, et al. (1997) A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 7: 1003-6. (Pubitemid 28017080)
33. Emery JG, McDonnell P, Burke MB, et al. (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273: 14363-7. (Pubitemid 28319153)
34. Ashkenazi A, Herbst RS (2008) To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 118: 1979-90. (Pubitemid 351872316)
35. Ravi R, Jain AJ, Schulick RD, et al. (2004) Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Can Res 64: 9105-14. (Pubitemid 39665525)
36. Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev 8: 782-98.
37. Yuan B-Z, Chapman J, Ding M, Wang J, Jiang B, et al. (2013) TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages. BMC Cancer 13: 140.
38. Wiezorek J, Holland P, Graves J (2010) Death Receptor Agonists as a Targeted Therapy for Cancer. Clin Cancer Res 16(6): 1701-8.
39. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, et al. (2006) Tumor invasion in the absence of epithelial-mesenchymal transition: podoplaninmediated remodeling of the actin cytoskeleton. Cancer Cell 9: 261-272.
40. Martín-Villar E, Fernández-Muñoz B, Parsons M, Yurrita MM, Megías D, et al. (2010) Podoplanin associates with CD44 to promote directional cell migration. Mol Biol Cell 21: 4387-4399.
41. Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, et al. (2007) The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 170: 1337-1347. (Pubitemid 47339340)
42. Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, et al. (2006) Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 107: 563-569. (Pubitemid 44107217)
43. Hoshino A, Ishii G, Ito T, Aoyagi K, Ohtaki Y, et al. (2011) Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression. Can Res 71: 4769-4779.
44. Kimura N, Kimura I (2005) Podoplanin as a marker for mesothelioma. Pathol Int 55: 83-86. (Pubitemid 40343728)
45. Singh S, Sadacharan S, Su S, Belldegrun A, Persad S, et al. (2003) Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Can Res 63: 2306-2311. (Pubitemid 36538641)
46. Gilles C, Polette M, Zahm JM, Tournier JM, Volders L, et al. (1999) Vimentin contributes to human mammary epithelial cell migration. J Cell Sci 112: 4615-4625. (Pubitemid 30034810)
47. Hendrix MJ, Seftor EA, Seftor RE, Trevor KT (1997) Experimental coexpression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol 150: 483-495. (Pubitemid 27073779)
48. Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, et al. (2002) Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 52: 253-263.
49. Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, et al. (2013) A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol 190(12): 6239-49.
50. Yang H, Wang Y, Cheryan VT, Wu W, Cui CQ, et al. (2012) Withaferin A Inhibits the Proteasome Activity in Mesothelioma In Vitro and In Vivo. PLoS ONE 7(8): e41214.
51. Van TT, Hanibuchi M, Kakiuchi S, Sato S, Kuramoto T, et al. (2011) The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Cancer Chemother Pharmacol 68: 497-504.
52. Krishnan H, Ochoa-Alvarez JA, Shen Y, Nevel E, Lakshminarayanan M, et al. (2013) Serines in the intracellular tail of podolplanin (PDPN) regulates cell motility. J Biol Chem 288: 12215-12221.
53. Komander D, Rape M (2012) The ubiquitin code. Annu Rev Biochem 81: 203-229.
54. Rieser E, Cordier SM, and Walczak H (2013) Linear ubiquitination: a newly discovered regulator of cell signaling. Trends in Biochemical Sci 38: 94-102.
55. Kyriakis JM, Avruch J (2012) Mammalian MAPK signal transduction pathways activated by stress and inflammation: A 10-year update. Physiol Rev 92: 689-737.
56. Biton S, Ashkenazi A (2011) NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-α feedforward signaling. Cell 145(1): 92-103.
57. McCool KW, Miyamoto S (2012) DNA damage-dependent NF-κB activation: NEMO turns nuclear signaling inside out. Immunological Reviews 246: 311-326.